Bbeta (15-42) and its analogues combined with cyclosporine for treatment of reperfusion injury
WO2010034041A1
Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
KR20110031280A
Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EP2193370A2
Methods of screening for compounds having anti-inflammatory activity
US2009286740A1
Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
US2009286725A1
Peptides and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
AT506121A1
Screening for compounds, e.g. proteins or peptides, that increase the activity of the protein Rac1 comprises contacting cultured endothelial cells with a test compound and measuring endothelial permeability
US2009081192A1
Methods of screening for compounds having anti-inflammatory activity
US2008004220A1
Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
ZA200807028B
Peptides and peptide derivatives as well as pharmaceutical compositions containing the same
WO2007095659A1
Peptides and peptide derivatives, preparation thereof and the use thereof for preparing a therapeutic and/or preventative medicament
AT502987A1
Pharmaceutical composition for the treatment of hemorrhagic shock and its affiliates
CN1842344A
Use of human fibrinogen a alpha or b beta chain peptide for treating shock
EP1691827A1
Use of peptides derived from the b beta chain of human fibronogen for the treatment of shock
AT501263A4
Treatment of shock, e.g. due to bacterial toxins or hemorrhagic shock associated with viral infections, comprises using peptides matching the inducible VE-cadherin binding moiety of human fibrin Bbeta-chain
EP1341819A2
Use of fibrin/fibrinogen peptides and proteins for the manufacture of a medicament
